Compare Incyte Corporation (INCY) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Payoneer Global Inc — how do they compare? Incyte Corporation trades at $121.08 (market cap $24.54B), while Payoneer Global Inc trades at $7.07 (market cap $2.40B). The key difference: Incyte Corporation is far larger — about 10.2× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | PAYO | |
|---|---|---|
Market Cap | $24.54B | $2.40B |
Sector | Health | Technology |
52-Week High | $129.93 | $7.17 |
52-Week Low | $81.61 | $4.27 |
Enterprise Value | $20.04B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Payoneer (PAYO) trades at $7.07, down 0.28% on the day, with a bullish technical signal from moving averages and an oversold RSI. Revenue grew to $821.16M in 2025, but net income fell to $73.19M, and Q2 2026 earnings missed estimates. The company is set to be acquired by Nuvei for $7.40 per share, pending shareholder approval, amid legal scrutiny over deal fairness.
The outlook is acquisition-driven, with upside limited to the $7.40 buyout price unless a higher bid emerges. Risks include integration challenges, earnings volatility, and legal disputes. Analysts maintain a buy consensus with an $8.20 target, suggesting potential gains if the deal proceeds smoothly, but caution is warranted due to recent profit margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
